Comparing Cisplatin Dosing Schedules in Concurrent Chemoradiotherapy for Locally Advanced Head-and-Neck Cancer: A Comprehensive Review of Weekly Versus 3-Weekly Regimens DOI Creative Commons

Oscar Chi-Yu Yang,

Nai-Wen Su,

Yi‐Shing Leu

et al.

Journal of Cancer Research and Practice, Journal Year: 2024, Volume and Issue: 11(4), P. 125 - 133

Published: Oct. 1, 2024

Abstract Objective: There are approximately 900,000 new cases of head-and-neck cancer (HNC) annually, with a significant proportion presenting as locally advanced (LA-HNC). Cisplatin-based concurrent chemoradiotherapy (CCRT) has become widely accepted, particularly for patients deemed inoperable. The standard regimen is high-dose 3-weekly cisplatin schedule, however, this can lead to considerable toxicities. This review evaluates the efficacy, safety, and compliance associated an emerging alternative: weekly dosing schedule. Data Sources: current literature included randomized controlled trials, meta-analyses, retrospective studies within past decade, comparing weekly, CCRT regimens LA-HNC. Study Selection: Studies cisplatin-based were included. Results: Weekly demonstrated comparable efficacy traditional lower toxicity improved compliance. Key suggested that may have more favorable safety profile, reduced risks neutropenia, renal impairment, ototoxicity. However, potential slightly better locoregional control remains point ongoing investigation. Novel agents including immune checkpoint inhibitors, xevinapant, berzosertib being actively investigated combinational therapies CCRT. Conclusion: viable alternative treating LA-HNC, in at higher risk Further trials required confirm optimal schedule novel agents. These findings underline importance exploring treatment protocols balance therapeutic benefits adverse effects

Language: Английский

What cancers explain the growing rural‐urban gap in human papillomavirus‐associated cancer incidence? DOI Creative Commons
Jason Semprini, Whitney E. Zahnd, Heather M. Brandt

et al.

The Journal of Rural Health, Journal Year: 2025, Volume and Issue: 41(1)

Published: Jan. 1, 2025

Human papillomavirus (HPV) can cause cancers of the genital system, anus/rectum, and oropharynx. Prior research showed that HPV-associated cancer incidence was rising faster in nonmetro than metro populations. Our study identified which contributed to widening disparity.

Language: Английский

Citations

1

Influence of the COVID-19 pandemic on the incidence and mortality of primary spinal tumors in the United States: A SEER analysis DOI
Wenbo Zhao, Kai Liu, Xiaoxu Fu

et al.

European Spine Journal, Journal Year: 2025, Volume and Issue: unknown

Published: March 31, 2025

Language: Английский

Citations

0

Impact of Presurgical Second‐Touch Visits on Delays in Initiating Adjuvant Radiation Therapy DOI
Antonio Bon‐Nieves, Naomi C. Wang, Sarah F. Wagoner

et al.

Otolaryngology, Journal Year: 2025, Volume and Issue: unknown

Published: April 10, 2025

Abstract Objective Patients with head and neck squamous cell carcinoma (HNSCC) often encounter delays in starting postoperative radiotherapy (PORT), leading to worse outcomes. We investigated whether attending second‐touch visits—appointments after the initial clinic visit before surgery address treatment‐related questions follow‐up expectations—with an advanced practice provider (APP) is associated reduced PORT delays. Study Design Retrospective cohort study. Setting Single tertiary referral center. Methods Adult patients HNSCC who underwent free flap between 2020 2022 were included. All offered a visit. The primary outcome was delay, defined as treatment initiation >42 days surgery. Clinicodemographic data collected at baseline last known follow‐up. Results Of 104 included, 57.7% attended Attendance receiving (RT) academic setting (65.0% vs 40.9%, P = .015) fewer (56.7% 79.5%, .015). Multivariable analysis revealed 70% reduction odds of delay for those visits (adjusted ratio [aOR] 0.298, 95% CI 0.103‐0.866, .026). more likely RT community (aOR 3.783, 1.284‐11.146, .016), wound complications 5.149, 1.363‐19.460, higher comorbidity index 1.407, 1.012‐1.957, .042). Conclusion medical center significantly likelihood delay. These findings underscore importance APP‐driven patient navigation improving timely care outcomes HNSCC.

Language: Английский

Citations

0

Análisis de la supervivencia de los pacientes con tumores malignos de cabeza y cuello diagnosticados durante la pandemia de COVID-19 DOI
Xavier León, Cristina Valero, Anna Holgado

et al.

Acta Otorrinolaringológica Española, Journal Year: 2025, Volume and Issue: 76(2), P. 106 - 115

Published: Feb. 16, 2025

Citations

0

Differences in the incidence and mortality of tracheal, bronchus, and lung cancer between the Global Cancer Observatory 2022 and the Global Burden of Disease 2021 DOI Creative Commons
Zhifei Li, Runze Li, Jianchuan Chen

et al.

Journal of the National Cancer Center, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0

The COVID‐19 pandemic and associated declines in cancer incidence by race/ethnicity and census‐tract level SES, rurality, and persistent poverty status DOI Creative Commons

Benmei Liu,

Mandi Yu,

Jeffrey Byrne

et al.

Cancer Medicine, Journal Year: 2024, Volume and Issue: 13(17)

Published: Sept. 1, 2024

The COVID-19 pandemic had a significant impact on cancer screening and treatment, particularly in 2020. However, no single study has comprehensively analyzed its effects incidence disparities among groups such as race/ethnicity, socioeconomic status (SES), persistent poverty (PP), rurality.

Language: Английский

Citations

1

The Effect of Coronavirus Disease 2019 and Other Emerging Infections on Dentistry DOI

Ramesh Balasubramaniam Oam,

Jaimin Patel, Karpagavalli Shanmugasundaram

et al.

Dental Clinics of North America, Journal Year: 2024, Volume and Issue: 68(4), P. 627 - 646

Published: Sept. 6, 2024

Language: Английский

Citations

0

Nasopharyngeal, tongue and laryngeal cancer in Southern Ethiopia: a seven-year retrospective cross-sectional review DOI Creative Commons
Achamyelesh Gebretsadik,

Netsanet Bogale,

Dereje Geleta

et al.

ecancermedicalscience, Journal Year: 2024, Volume and Issue: 18

Published: Oct. 8, 2024

The burden of cancer is increasing globally and having a negative impact on people's physical, mental financial health. On the other hand, developing countries are not progressing to prevent disease at same rate as increases. development strategies for prevention, control treatment that contribute community's improved health requires knowledge epidemiologic data. There relatively little evidence nasopharyngeal, tongue laryngeal in southern Ethiopia. This study aimed assess epidemiological among patients treated Hawassa University Comprehensive Specialised Hospital (HUCSH) between 2013 2019. A cross-sectional retrospective review was conducted 3,002 who attended oncologic care HUCSH. Data were retrieved February May 2020. entered using Epi-data version 3.1 data then exported IBM SPSS 22 (IBM Corporation, Armonk, NY, USA) further processing analysis. descriptive analysis done. total 280 (9.3%) new head neck (HNC) identified over period 7 years. Nasopharyngeal accounts more than one-fourth (26.4%) all HNCs, followed by 15% 14.6% cancers. Males constituted nearly two-thirds cases. overall caseloads doubled According this study, prominent cause morbidity. place, person time, frequency steadily rose both sexes across age categories. Therefore, immediate intervention needed nationwide monitor disease's explosive growth.

Language: Английский

Citations

0

Impact of Symptom Distress on the Quality of Life of Oncology Palliative Care Patients: A Portuguese Cross-Sectional Study DOI Open Access
Florbela Gonçalves, Margarida Gaudêncio, Ivo Paiva

et al.

Healthcare, Journal Year: 2024, Volume and Issue: 12(23), P. 2487 - 2487

Published: Dec. 9, 2024

Uncontrolled symptoms are widely recognized as one of the main challenges in oncology palliative care patients. The central aim is to improve patient's quality life. In recent years, there has been a growing use patient-reported outcome measures care, particularly evaluate symptoms, and well-being.

Language: Английский

Citations

0

Comparing Cisplatin Dosing Schedules in Concurrent Chemoradiotherapy for Locally Advanced Head-and-Neck Cancer: A Comprehensive Review of Weekly Versus 3-Weekly Regimens DOI Creative Commons

Oscar Chi-Yu Yang,

Nai-Wen Su,

Yi‐Shing Leu

et al.

Journal of Cancer Research and Practice, Journal Year: 2024, Volume and Issue: 11(4), P. 125 - 133

Published: Oct. 1, 2024

Abstract Objective: There are approximately 900,000 new cases of head-and-neck cancer (HNC) annually, with a significant proportion presenting as locally advanced (LA-HNC). Cisplatin-based concurrent chemoradiotherapy (CCRT) has become widely accepted, particularly for patients deemed inoperable. The standard regimen is high-dose 3-weekly cisplatin schedule, however, this can lead to considerable toxicities. This review evaluates the efficacy, safety, and compliance associated an emerging alternative: weekly dosing schedule. Data Sources: current literature included randomized controlled trials, meta-analyses, retrospective studies within past decade, comparing weekly, CCRT regimens LA-HNC. Study Selection: Studies cisplatin-based were included. Results: Weekly demonstrated comparable efficacy traditional lower toxicity improved compliance. Key suggested that may have more favorable safety profile, reduced risks neutropenia, renal impairment, ototoxicity. However, potential slightly better locoregional control remains point ongoing investigation. Novel agents including immune checkpoint inhibitors, xevinapant, berzosertib being actively investigated combinational therapies CCRT. Conclusion: viable alternative treating LA-HNC, in at higher risk Further trials required confirm optimal schedule novel agents. These findings underline importance exploring treatment protocols balance therapeutic benefits adverse effects

Language: Английский

Citations

0